Recital 6, Regulation (EU) 2026/397

In forcesince 23 Feb 2026

On 15 October 2023, the applicant also made a request to the Commission for the protection of the proprietary scientific studies and data, namely, identity of the novel food [Section 2.1; Annex 2.1.01 to the application (NMR report LNT Inbiose); Annex 2.1.02 to the application (NMR shifts of LNT); Annex 2.1.03 to the application (LNT_UPLC-RI validation report INBMV1002_2021); Annex 2.1.03.01 to the application (UPLC-RI_Analytical standards CoA); Annex 2.1.04 to the application (UPLC-MSMS analysis_LNT); Annex 2.1.05 to the application (Additional NMR spectra).], production process, including information on the genetically modified production strain [Section 2.2; (Protocol for the preparation of master and working cell banks – Inbiose N.V.); Annex 2.2.04 to the application (GMM_description INB_LNT and GMM_description INB_LNT_01_updated_2024); Annex 2.2.04.02 to the application (Structure helper plasmids INB_LNT_01 and Structure and sequence helper plasmids INB_LNT_01_updated_2024); Annex 2.2.04.03 to the application (Recombinant genes INB_LNT_01); Annex 2.2.04.04 to the application (Amino acid sequences recombinant proteins INBLNT_01); Annex 2.2.04.05 to the application (Genetic information); Annex 2.2.04.06 to the application (Genomic maps of gene deletions); Annex 2.2.04.07 to the application (Contigs_LNT_fasta_file_updated_2024, full document); Annex 2.2.04.08 to the application (PROKKA_LNT_fasta file of predicted AA); Annex 2.2.04.09 to the application (LNT_Deposition certificate); Annex 2.2.04.10 to the application (Structure and sequence pINB_LNT_01); Annex 2.2.04.11 to the application (Additional AMR INB_LNT_01); Annex 2.2.04.12 to the application (Test for absence of viable cells); Annex 2.2.05 to the application (Raw materials); Annex 2.2.06 to the application (Differences pilot vs commercial); Annex 2.2.07 to the application (HACCP plan); Annex 2.2.08 to the application; Annex 2.2.08.01 to the application; Annex 2.2.09 to the application ((HACCP plan_2019).], composition and stability of the novel food [Section 2.3; Annex 2.3.01 to the application (ash content); Annex 2.3.02 to the application (carbohydrates); Annex 2.3.03 to the application (endotoxins); Annex 2.3.04 to the application (Enterobacteriaceae); Annex 2.3.05 to the application (pH analysis); Annex 2.3.06 to the application (Microbiology); Annex 2.3.07 to the application (Protein content); Annex 2.3.08 to the application (Water content); Annex 2.3.09 to the application (Heavy metals); Annex 2.3.10 to the application (Mycotoxins); Annex 2.3.11 to the application (Absence of rDNA); Annex 2.3.12 to the application (Method description results qNMR (Inbiose)); Annex 2.3.12.01 to the application (Method Validation: Quantitative Nuclear Magnetic Resonance (qNMR) Measurement); Annex 2.3.13 to the application (Minor carbohydrates UPLC-RI); Annex 2.3.14.01 to the application (Determination of HMOs by LC-MSMS); Annex 2.3.14.02 to the application (Validation report_LC-MSMS); Annex 2.3.15 to the application ((LNT solubility report and LNT solubility report_updated_2024); Annex 2.3.16 to the application (Calculation matrix composition LNT; Excel sheet: LNT spec.; Excel sheet: qNMR LNT % DM); Annex 2.3.18 to the application (Inbiose’s LNT_Stability study_Powder 40C 70RH); Annex 2.3.19 to the application (Summary stability study LNT 40 °C_75 % RH; Excel sheet: 40_75; Excel sheet: graphs 40_75; Excel sheet: microbio); Annex 2.3.20 to the application (Inbiose’s LNT_Stability study_Powder 25C 60RH and Inbiose’s LNT_Stability study_Powder 25C 60RH_CONFIDENTIAL_Updated_updated_2024); Annex 2.3.21 to the application (Summary stability study LNT 25 °C_60 % RH Excel sheet: 25_60 Excel sheet: graphs 25_60 Excel sheet: microbio and Summary stability study LNT 25 °C_60 %; RH_Updated_updated_2024; Excel sheet: 25_60; Excel sheet: graphs 25_60; Excel sheet: microbio); Annex 2.3.22 to the application (Inbiose’s LNT_Stability study_Liquid food matrices); Annex 2.3.23 to the application (Inbiose’s LNT_Stability study_Infant formula); Annex 2.3.24 to the application (Manufacturing of the infant formula); Annex 2.3.30 to the application (Peak identification LNT); Protocol for the preparation of master and working cell banks – Inbiose N.V.; P1512_R03_v01 –17 NOV 2020; P1679_R01_v01_INB_signed); P1512_R03_v01 –17 NOV 2020 (method description for monitoring HMOs in food ingredients and food matrices); P1679_R01_v01_INB_signed (evaluation of alternative filter membrane for sample preparation in hmo lc-ms method).], Absorption, Distribution, Metabolism and Excretion (ADME) [Section 2.7.], toxicological information [Section 2.9; Subsection 2.9.2 (Mutagenicity and genotoxicity studies); Subsection 2.9.3 (Sub-chronic oral toxicity study in the rat); Annex 2.9.01 to the application (Mutagenicity study LNT OECD 471); Annex 2.9.02 to the application (Genotoxicity study LNT OECD 487); Annex 2.9.03 to the application (OECD 408 formulation analyses); Annex 2.9.04 to the application (Report Validation urine analysis); Annex 2.9.05 to the application (Validation plasma analysis); Annex 2.9.06 to the application (Dose-range finding study); Annex 2.9.07 to the application (Report subchronic oral tox study LNT OECD 408); Appendix B.3 (the summary table of statistically significant observations in toxicity studies).], and the bioinformatic study for allergenicity assessment [Annex 2.10.01 to the application (allergen results).], in support of the application.